GLP‑1 Drugs Drive New Treatments, Coverage Plans and Safety Scrutiny
A recent double‑blind trial in Denmark found that semaglutide reduced alcohol consumption and heavy‑drinking days among participants with alcohol‑use disorder, suggesting GLP‑1 drugs may help treat substance addictions.
The U.S. Centers for Medicare & Medicaid Services will launch a GLP‑1 Bridge program in July, extending through 2027, to allow Medicare beneficiaries to obtain coverage for GLP‑1 weight‑loss medications when prescribed, although the cost will be billed outside Part D limits.
Social‑media misinformation about GLP‑1 drugs is widespread; experts emphasise that these medications are prescription tools for metabolic conditions and must be used under medical supervision rather than as cosmetic shortcuts.
A safety analysis of FDA adverse‑event reports linked Wegovy (semaglutide) to a markedly higher reporting odds of ischemic optic neuropathy, a rare cause of sudden vision loss, especially in men, though causality has not been proven.
Rapid weight loss from GLP‑1 therapy is creating a new demand for facial aesthetic procedures in Brazil, as patients seek to restore volume and skin quality after swift fat reduction.
Clinical data show Wegovy works by mimicking the GLP‑1 hormone to curb hunger, increase satiety, slow gastric emptying and improve blood‑sugar regulation.
A large U.S. real‑world study of nearly 90 000 patients on GLP‑1 or GLP‑1/GIP drugs found that those who lost ≥15 % of BMI had significantly lower risks of osteoarthritis, chronic kidney disease, obstructive sleep apnea and heart failure, highlighting broader health benefits tied to weight loss.